Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
GEN detailed milestone breakdown: ~$790M for demcizumab, ~$505M for the anti-DLL4/VEGF bispecific, ~$440M for each of four additional biologics, and >$100M for…
Nature Biotechnology framed the OncoMed pact as part of Celgene's 'multibillion spree,' emphasizing the heavy reliance on optioned, milestone-laden deals to…
Two years after signing, demcizumab was being positioned as a potential blockbuster within Celgene's pipeline pending readout of the DENALI (1L NSCLC) and…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Celgene/OncoMed global co-dev/co-commercialization for demcizumab plus 5 cancer stem cell biologics; ~$155M upfront + $22.25M equity + ~$3B in potential milestones plus royalties.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / OncoMed Pharmaceuticals, Inc. (this deal) | 2013 | $3.3B | 10 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2013 deals · Celgene Corporation deals · Oncology deals